Insulet Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Ashley McEvoy
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1yr |
| CEO ownership | 0.006% |
| Management average tenure | 1.2yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
Long-Term Diabetes Automation Adoption And Manufacturing Scale Will Drive Strong Future Potential
Catalysts About Insulet Insulet provides tubeless automated insulin delivery systems through its Omnipod platform for people living with diabetes worldwide. What are the underlying business or industry changes driving this perspective?Insulet: The Growth Doesn't Stop Here
Feb 27Insulet Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 09
Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher
Sep 06There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings
Aug 14Insulet (NASDAQ:PODD) Has A Rock Solid Balance Sheet
Aug 04Does Insulet (NASDAQ:PODD) Deserve A Spot On Your Watchlist?
Jul 22Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Jun 25What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?
May 28Subdued Growth No Barrier To Insulet Corporation (NASDAQ:PODD) With Shares Advancing 26%
May 15We Ran A Stock Scan For Earnings Growth And Insulet (NASDAQ:PODD) Passed With Ease
Apr 21Insulet Leans Bullish (Technical Analysis)
Mar 18Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Nov 20Insulet: Turning More Constructive, Valuations Still Stretched
Sep 05CEO
Ashley McEvoy (54 yo)
Ms. Ashley A. McEvoy serves as Chief Executive Officer, President and Director of Insulet Corporation since April 28, 2025. She serves as Independent Director of The Procter & Gamble Company since December...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP & CFO | less than a year | US$602.93k | 0.0016% $ 224.1k | |
| Executive VP & COO | less than a year | US$4.14m | 0.023% $ 3.2m | |
| Senior VP & General Counsel | 7.1yrs | US$2.91m | 0.033% $ 4.7m | |
| CEO, President & Director | 1yr | no data | 0.0063% $ 890.9k | |
| Senior VP & CTO | 1.1yrs | no data | no data | |
| Vice President of Investor Relations | 1.3yrs | no data | no data | |
| Senior VP of Regulatory Affairs | 3.3yrs | no data | 0.0082% $ 1.2m | |
| Senior Director of Corporate Communications | no data | no data | no data | |
| Senior Vice President of Sales & Customer Care | 11.3yrs | no data | no data | |
| Senior VP of Strategy & Corporate Development | 2yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | less than a year | no data | no data | |
| Senior VP & Chief Medical Officer | no data | no data | no data |
Experienced Management: PODD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1yr | no data | 0.0063% $ 890.9k | |
| Independent Chair | 4.2yrs | US$333.46k | 0.0064% $ 907.8k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Educator Advisory Board | no data | no data | no data | |
| Member of Educator Advisory Board | no data | no data | no data | |
| Member of Educator Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Educator Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.3yrs | US$607.42k | 0.0044% $ 625.9k | |
| Independent Director | 10.8yrs | US$313.46k | 0.039% $ 5.5m |
Experienced Board: PODD's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 13:31 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Insulet Corporation is covered by 47 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Matthew Miksic | Barclays |
| Travis Steed | Barclays |